

Supplemental Data

Human Aldehyde Oxidase 1-mediated Carbazeran Oxidation in Chimeric TK-NOG Mice Transplanted with Human Hepatocytes


Shotaro Uehara, Nao Yoneda, Yuichiro Higuchi, Hiroshi Yamazaki, and Hiroshi Suemizu

Laboratory Animal Research Department, Central Institute for Experimental Animals, Kawasaki, Kanagawa 210-0821, Japan (SU, NY, YH, and HS); and the Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan (HY).

Drug Metabolism and Disposition


Supplemental Figure 1

Kinetics of carbazeran 4-oxidation by liver cytosol (A) and recombinant human AOX1 (B). Kinetic analyses of carbazeran 4-oxidation by the liver cytosol from humans (circles), humanized-liver mice (squares), and control mice (triangles). Data represent the mean of duplicate determinations.



Supplemental Figure 2

Chromatographic profile of carbazeran and its metabolites in urine after oral administration of carbazeran to humanized-liver mice (A) and control mice (B). Urine samples were analyzed by mass detection of m/z 361.0 (carbazeran), 377.0 (M1), 349.0 (M2), 306.0 (M3), and 347.0 (M4).



Supplemental Figure 3

The MS/MS spectra of carbazeran metabolites M2 (A), M3 (B), and M4 (C). Urine samples were analyzed with the data-dependent MS₂ scanning mode using the following settings: polarity, positive; normalized collision energy, 30 V; precursor ion, *m/z* 349.0 (A), *m/z* 306.0 (B), and *m/z* 347.0

